Individualized cancer immunotherapy

Genocea Presents Updated Long-term Safety, Immunogenicity and Durability Data from GEN-009 Neoantigen Vaccine Phase 1/2a Trial Part A at Virtual ASCO 2020

Friday, May 29, 2020 - 1:00pm

CAMBRIDGE, Mass., May 29, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today presents updated durability, safety and immunogenicity clinical data from Part A of its ongoing Phase 1/2a trial for GEN-009, the companys lead neoantigen vaccine candidate.

Key Points: 
  • CAMBRIDGE, Mass., May 29, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today presents updated durability, safety and immunogenicity clinical data from Part A of its ongoing Phase 1/2a trial for GEN-009, the companys lead neoantigen vaccine candidate.
  • Title: GEN-009, a neoantigen vaccine containing ATLAS-selected neoantigens, to generate broad sustained immunity against immunogenic tumor mutations and avoid inhibitory peptides.
  • Seven out of the eight patients enrolled have continued without progression with a median follow up of over one year.
  • No significant adverse side effects were reported with the administration of GEN-009, with only mild symptoms associated with the vaccine adjuvant.

Transgene and NEC Demonstrate High Accuracy of AI-based Neoantigen Prediction for the Design of Individualized Cancer Vaccine TG4050

Friday, May 15, 2020 - 6:10am

To evaluate the accuracy of the prediction, samples from cancer patients were collected.

Key Points: 
  • To evaluate the accuracy of the prediction, samples from cancer patients were collected.
  • Title of the poster: Performance of neoantigen prediction for the design of TG4050, a patient specific neoantigen cancer vaccine
    The abstract can be downloaded on the AACR website.
  • This virus-based therapeutic vaccine encodes neoantigens (patient-specific mutations) identified and selected by NEC's Neoantigen Prediction System.
  • For more information, visit NEC at https://www.nec.com.For additional information, please also visit NEC Laboratories Europe GmbH at: http://www.neclab.eu

Genocea to Present Long-term Follow-up Data from GEN-009 Neoantigen Vaccine at Virtual ASCO 2020

Wednesday, May 13, 2020 - 11:02pm

Seven out of the eight patients enrolled have continued without progression with a median follow up of over one year.

Key Points: 
  • Seven out of the eight patients enrolled have continued without progression with a median follow up of over one year.
  • No significant adverse side effects were reported with the administration of GEN-009, with only mild symptoms associated with the vaccine adjuvant.
  • Title: GEN-009, a neoantigen vaccine containing ATLAS selected neoantigens, to generate broad sustained immunity against immunogenic tumor mutations and avoid inhibitory peptides.
  • Genocea cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties that change over time.

Neoantigen-based Personalized Cancer Therapeutic Vaccines Competitive Landscape and Market Forecast 2035

Thursday, April 23, 2020 - 1:06pm

Neoantigen-based Personalized Cancer therapeutic Vaccines allows the immune system to recognize cancer cells as foreign, and therefore, get the immune system to attack the cancer cells.

Key Points: 
  • Neoantigen-based Personalized Cancer therapeutic Vaccines allows the immune system to recognize cancer cells as foreign, and therefore, get the immune system to attack the cancer cells.
  • Neoantigen-based Personalized Cancer therapeutic Vaccines are one way to utilize the body's immune system to fight cancer.
  • Click here to know more on Competitive Landscape of Neoantigen-based Personalized Cancer Therapeutic Vaccines.
  • The pipeline of Neoantigen-based Personalized Cancer therapeutic Vaccines appears to be very promising with availability of vaccines in different stages of development.

Neoantigen-based Personalized Cancer Therapeutic Vaccines Competitive Landscape and Market Forecast 2035

Thursday, April 23, 2020 - 1:03pm

Neoantigen-based Personalized Cancer therapeutic Vaccines allows the immune system to recognize cancer cells as foreign, and therefore, get the immune system to attack the cancer cells.

Key Points: 
  • Neoantigen-based Personalized Cancer therapeutic Vaccines allows the immune system to recognize cancer cells as foreign, and therefore, get the immune system to attack the cancer cells.
  • Neoantigen-based Personalized Cancer therapeutic Vaccines are one way to utilize the body's immune system to fight cancer.
  • Click here to know more on Competitive Landscape of Neoantigen-based Personalized Cancer Therapeutic Vaccines.
  • The pipeline of Neoantigen-based Personalized Cancer therapeutic Vaccines appears to be very promising with availability of vaccines in different stages of development.

EpiVax Oncology Inc. Announces It Has Reduced the Timeline of Its Personalized Neoantigen Therapeutic Cancer Vaccine Process to Under Four Weeks

Thursday, March 26, 2020 - 8:42pm

EpiVax Oncology, Inc ., a precision cancer immunotherapy company, today announced it has reduced the timeline from biopsy to vaccine to under 4 weeks for its personalized neoantigen therapeutic cancer vaccines.

Key Points: 
  • EpiVax Oncology, Inc ., a precision cancer immunotherapy company, today announced it has reduced the timeline from biopsy to vaccine to under 4 weeks for its personalized neoantigen therapeutic cancer vaccines.
  • Previously, the process to create an a personalized vaccine starting from tumor biopsy took at least 12 to 18 weeks.
  • With a personalized cancer vaccine process under 4 weeks, we can safely create a vaccine to treat all stages of aggressive cancer including in the neoadjuvant, adjuvant and metastatic setting.
  • EpiVax Oncology's personalized vaccine design platform, Ancer, incorporates the world-class EpiMatrix system and the innovative JanusMatrix tool, which were exclusively licensed to EpiVax Oncology by EpiVax.

BioNTech to acquire Neon to strengthen global leadership position in T cell therapies

Thursday, January 16, 2020 - 12:30pm

Neon is a biotechnology company developing novel neoantigen-based T cell therapies.

Key Points: 
  • Neon is a biotechnology company developing novel neoantigen-based T cell therapies.
  • I am particularly excited about the adoptive T cell and neoantigen TCR therapies being developed by Neon, which are complementary to our pipeline and our focus on solid tumors.
  • Neon has deep expertise in the development of neoantigen therapies, with both vaccine and T-cell capabilities.
  • Neon is also advancing a precision T cell therapy program targeting shared neoantigens in genetically defined patient populations.

BioNTech to acquire Neon to strengthen global leadership position in T cell therapies

Thursday, January 16, 2020 - 12:30pm

Neon is a biotechnology company developing novel neoantigen-based T cell therapies.

Key Points: 
  • Neon is a biotechnology company developing novel neoantigen-based T cell therapies.
  • I am particularly excited about the adoptive T cell and neoantigen TCR therapies being developed by Neon, which are complementary to our pipeline and our focus on solid tumors.
  • Neon has deep expertise in the development of neoantigen therapies, with both vaccine and T-cell capabilities.
  • Neon is also advancing a precision T cell therapy program targeting shared neoantigens in genetically defined patient populations.

Avidea Technologies Utilizes GenScript's Synthesized Neoantigen Peptides for Novel Personalized Cancer Vaccine

Wednesday, January 15, 2020 - 12:30pm

PISCATAWAY, N.J., Jan. 15, 2020 /PRNewswire/ -- GenScript , a world leading biotechnology company, announced its support today of Avidea Technologies' efforts to develop a groundbreaking peptide-based personalized cancer vaccine.

Key Points: 
  • PISCATAWAY, N.J., Jan. 15, 2020 /PRNewswire/ -- GenScript , a world leading biotechnology company, announced its support today of Avidea Technologies' efforts to develop a groundbreaking peptide-based personalized cancer vaccine.
  • Developing and validating SNP-7/8a as a personalized cancer vaccine required synthesis of hundreds of unique neoantigen peptides, which were successfully synthesized by Genscript in support of this work.
  • The publication is particularly timely as personalized cancer vaccines are garnering increasing attention among the scientific and medical community as important components to enabling precision immuno-oncology.
  • To support this work, GenScript synthesized hundreds of challenging neoantigen peptides that were selected to have a wide range of properties, including neoantigen peptides with extremes of net charge and hydrophobicity, which was instrumental to enabling Avidea and NIH scientists to validate the generalizability of the SNP-7/8a platform as a personalized cancer vaccine.